美國居民不適用 XM 服務。

What to Watch in the Day Ahead - Thursday, August 8



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>What to Watch in the Day Ahead - Thursday, August 8</title></head><body>

The Day Ahead is an email and PDF publication that includes the day's major stories and events, analyses and other features. To receive The Day Ahead, Eikon users can register at DAY/US. Thomson One users can register at RT/DAY/US. All times in ET/GMT

The Labor Department's weekly jobless claims report will be widely watched by investors after weaker-than-expected July jobs data last week fueled to a stock market rout. The report for the week ended August 3 is likely to show initial claims for unemployment benefits rose to 240,000, compared with 249,000 reported in the previous week. Continued jobless claims is expected to come in at 1.870 million for the week ended July 27, compared with 1.877 million in the previous week. Separately, wholesale inventories likely remained unchanged at 0.2% in June.


U.S. drugmaker Eli Lilly is scheduled to report second-quarter results before markets open, where investors would closely focus on sales and supply-related updates for its blockbuster diabetes drug Mounjaro and obesity drug Zepbound. Any updates about the launch of its recently approved Alzheimer's drug donanemab/Kisunla will also be of interest. Separately, Novavax is slated to report its second-quarter earnings. Investors are likely to look at the company's forecast for the fall COVID-19 vaccination demand as well as management commentary on their COVID-influenza combination vaccine trials. Additionally, Gilead Sciences is slated to release its second-quarter results. Investor focus will be on the demand for its cancer drugs and HIV products. The company is also expected to comment on its HIV drug, lenacapavir, and liver disease drug seladelpar that is eyeing an FDA approval later this year.


Richmond Fed President Thomas Barkin is scheduled to speak before a National Association for Business Economics webinar. (1500 /1900)


News Corp is expected to post higher fourth-quarter results, likely to be driven by a surge in digital subscriptions at business information unit Dow Jones.


Paramount Global is expected to report a fall in revenue in the second quarter as advertisers cut back on spending in an uncertain economy.


Trade Desk is likely to post a jump in second-quarter revenue as demand for ads from some sectors grow.


In Latin America, Mexico's national statistics agency is expected to report headline inflation for July likely rose to 1.02% from 0.38% in June. In the 12 months through July, inflation is expected have increased to 5.57%. The country's core inflation likely gained 0.29% in July, compared to a 0.22% rise in June. The country's July producer prices index (PPI) data is also due. Separately, Chile's inflation likely rose to 0.63% in July, after dropping to 0.10% in June. Argentina's industrial output data for June is slated for release. Meanwhile, Mexico and Peru's central banks are expected to keep their benchmark interest rates unchanged when announcing their respective policy decisions.


LIVECHAT- REUTERS GLOBAL MARKETS FORUM

Michael Ashley Schulman, CIO of Running Point Capital, a New York-based multifamily office, will run through equity and credit market scenarios post-Presidential and Congressional elections. (1100/1500) To join the discussion, email us here






Compiled by Dhanya Manjunath Hegade in Bengaluru; Editing by Shreya Biswas

</body></html>

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明